These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 15830256)
1. [The 12th amendment to the German Drug Law. Chances and obstacles for investigator-initiated clinical trials]. Dreier G; Marx C; Schmoor C; Maier-Lenz H Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):445-52. PubMed ID: 15830256 [TBL] [Abstract][Full Text] [Related]
2. [The community clinical trial system EudraCT at the EMEA for the monitoring of clinical trials in Europe]. Krafft H Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):453-8. PubMed ID: 15830257 [TBL] [Abstract][Full Text] [Related]
3. [Consequences of the 12th AMG amendment on the conduct of non-commercial clinical trials]. Rossion I Urologe A; 2005 Dec; 44(12):1444-8. PubMed ID: 16283155 [TBL] [Abstract][Full Text] [Related]
4. Academic investigator-initiated trials and the challenge of sponsor responsibility: the Cologne Sponsor Model. Georgias C; Grunow A; Olderog M; May A; Paulus U Clin Trials; 2012 Dec; 9(6):781-7. PubMed ID: 23104975 [TBL] [Abstract][Full Text] [Related]
5. [Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law]. Benninger-Döring G; Boos J Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Jul; 49(7):675-80. PubMed ID: 16763801 [TBL] [Abstract][Full Text] [Related]
6. [Recording and reporting adverse reactions in clinical trials. New legal provisions according to the 12th Law Amending the German Drug Law (AMG) and the Ordinance on GCP (GCP-V)]. Eckhardt K; Cremer-Schaeffer P; König J; Paeschke N Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):173-80. PubMed ID: 15726458 [TBL] [Abstract][Full Text] [Related]
7. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations]. Kölch M; Lippert HD; Fegert JM Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597 [TBL] [Abstract][Full Text] [Related]
8. [Harmonisation of regulatory requirements for clinical trials on medicinal products for human use in the Directive 2001/20/EC and complementary guidance. Implementation of the 12th Law Amending the German Drug Law]. Geisler I; Hofmann HP; Nickel L Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):141-6. PubMed ID: 15726454 [TBL] [Abstract][Full Text] [Related]
9. [The 12th German Drug Law (AMG) amendment: an obstruction for non-commercial clinical trials?]. Schwarz S; Frölich L; Striebel JP; Hennerici MG Dtsch Med Wochenschr; 2007 Jan; 132(3):108-12. PubMed ID: 17219346 [No Abstract] [Full Text] [Related]
10. [Assessment of SUSARs. Clinical evaluation of single cases in terms of regulatory requirements]. Wroblewski H; Schmickler M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):459-63. PubMed ID: 15830258 [TBL] [Abstract][Full Text] [Related]
11. [Clinical trials with minors in Germany--effects of the 12th amendment to the German Drug Code on the numbers of applications to Institutional Review Boards (IRB)]. Kölch M; Märsch C; Fegert JM; Lippert HD Gesundheitswesen; 2009 Mar; 71(3):127-33. PubMed ID: 19221985 [TBL] [Abstract][Full Text] [Related]
12. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view]. Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252 [TBL] [Abstract][Full Text] [Related]
13. [Effects of the 12th amendment to the German drug code on investigator-initiated clinical trials]. Kehrel U Gesundheitswesen; 2011 Oct; 73(10):696-701. PubMed ID: 20859850 [TBL] [Abstract][Full Text] [Related]
14. [Clinical trials for medicinal products. New European and national legal rules]. Kreutz G Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 May; 48(5):524-9. PubMed ID: 15887061 [TBL] [Abstract][Full Text] [Related]
15. [Clinical drug investigations. Definition of terms]. Johne A; Gerloff T; Mai I Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):397-400. PubMed ID: 15830249 [TBL] [Abstract][Full Text] [Related]
17. [Reorganization of the procedures and the tasks of the responsible ethics committees after the 12th AMG amendment. Concepts of the permanent working group of the medical ethics committees in Germany]. Wessler I; Burger R; Doppelfeld E Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):155-67. PubMed ID: 15726456 [TBL] [Abstract][Full Text] [Related]
18. [Clinical research with pharmaceutical agents in Germany: effects of the 12th amendment to the German Drug Law]. Götte D; Weihrauch TR Internist (Berl); 2004 Jun; 45 Suppl 1():S48-54. PubMed ID: 15138642 [TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology policy statement: oversight of clinical research. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281 [TBL] [Abstract][Full Text] [Related]
20. [Regulatory aspects of clinical trials with emphasis on biologicals]. Volkers P; Poley-Ochmann S; Nübling M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):408-14. PubMed ID: 15830251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]